A Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery
Key facts
- Who runs it
- Biotech Healthcare Holding Gmbh
- Where
- Germany, India, and Spain6 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 138 people, planned
- Started
- 22 Nov 2021
- Expected to end
- Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Optiflex TRIO Intraocular Lens
- AcrySof® IQ PanOptix®
- Record updated
- 18 November 2025
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age of patient >21 Years
- Patient diagnosed with cataract
- Patient must have preoperative regular corneal astigmatism between 0.75 to 4.5 D as per corneal topography or keratometry
- Calculated IOL power is within the range of investigational IOLs
- Patient willing to sign inform consent form
- Clear intraocular media other than cataract
- Female participants of childbearing potential must be willing to ensure that they use effective contraception during the study
Who cannot take part
- Previous intraocular or corneal surgery
- Concurrent participation in another drug or device investigation
- Patient receiving chlorquine treatment
- Subjects with any systemic disease that could increase operative risk or confound the outcome
- Active ocular disease in the operative eye other than cataract
- Traumatic cataract
- Pregnancy (as stated by patient) or lactation
- Irregular astigmatism
- Vulnerable subjects as defined in section 12.3.9
- Corneal Astigmatism > 4.5 D
This trial is currently available in Germany, India, and Spain.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the clinical outcomes and patient satisfaction of two commercially available trifocal toric intraocular lenses Primary Objective: To compare the distance-corrected intermediate visual acuity between the two trifocal toric intraocular lenses. Secondary Objectives: To assess and compare the safety of two trifocal toric intraocular lenses.
The 2 groups in the trial
- Optiflex TRIO (Biotech Europe Meditech Inc. Ltd.)Treatment being tested
Patients will be implanted with Optiflex TRIO (Biotech Europe Meditech Inc. Ltd.) IOL based on randomization
Treatment: Optiflex TRIO Intraocular Lens
- AcrySof® IQ PanOptix® (Alcon Laboratories, Inc.)Existing treatment, for comparison
Patients will be implanted with AcrySof® IQ PanOptix® (Alcon Laboratories, Inc.) based on randomization
Treatment: AcrySof® IQ PanOptix®
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter Clinical Study Comparing Outcomes of Two Trifocal Toric Intraocular Lens
- Record updated
- 18 November 2025